Portfolio

SkinJect_72

A novel drug delivery using a dissolvable microneedle array that would both treat – and potentially prevent the recurrence of – basal cell and squamous cell skin cancer. SkinJect will offer an effective way to eliminate existing non-melanoma skin cancers while potentially preventing recurrence as well as providing a safe, convenient way to deliver therapy.

Sector: Drug Delivery

Year Funded: 2016

InClinica_2c

A global, clinical CRO that leads companies through clinical trials, with a special strength assisting small to mid-sized companies that are entering first-in-man and phase two trials. InClinica’s senior leadership team has extensive experience in drug development and clinical trial management and brings access to world-class experts who are critical to trial design and execution.

Sector: Medical Services

Year Acquired: 2016

Signalence logo

Signalence develops innovative solutions to “signal” detection. These signals can range from signs of illicit covert communication to signs or symptoms of disease. Our inventions are designed to capture signals, interpret their meaning, and help the user take the necessary steps to address the “signs” of a problem.